Journal of Parkinsons Disease

Papers
(The H4-Index of Journal of Parkinsons Disease is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
A framework to standardize gait study protocols in Parkinson's disease101
This is NOT the End for Immunotherapy in Parkinson’s Disease – A Perspective from Early Drug Development Scientists82
Clinical Trial Highlights: Modulators of Mitochondrial Function71
Introduction: The Earliest Phase of Parkinson’s Disease: Possibilities for Detection and Intervention63
One-year practice effects predict long-term cognitive outcomes in Parkinson's disease53
Chronotropic Incompetence in Parkinson’s Disease: A Possible Marker of Severe Disease Phenotype?53
Glucocerebrosidase Activity is Reduced in Cryopreserved Parkinson’s Disease Patient Monocytes and Inversely Correlates with Motor Severity51
Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression51
Imaging Biomarkers in Prodromal and Earliest Phases of Parkinson’s Disease50
May Bradykinesia Features Aid in Distinguishing Parkinson’s Disease, Essential Tremor, And Healthy Elderly Individuals?49
A possible pathway to freezing of gait in Parkinson's disease44
The fixel GI Parkinson's research and integrated support model (PRISM)44
A Multisensory Deficit in the Perception of Pleasantness in Parkinson’s Disease43
Early-Onset Parkinson’s Disease: Creating the Right Environment for a Genetic Disorder43
Predictive Value of Verbatim Parkinson’s Disease Patient-Reported Symptoms of Postural Instability and Falling41
Clinical Trial Highlights – Aerobic Exercise for Parkinson’s Disease39
Is There an Association Between Parkinson’s Disease and Periodontitis? A Systematic Review and Meta-Analysis39
Cerebral Small Vessel Disease Is Associated with Motor, Cognitive, and Emotional Dysfunction in Multiple System Atrophy39
Jellinger K, “Parkinson’s Disease and Dementia with Lewy Bodies: One and the Same”38
Cost-Effectiveness and Cost-Utility of Early Levodopa in Parkinson’s Disease38
Ethical Considerations for Identifying Individuals in the Prodromal/Early Phase of Parkinson’s Disease: A Narrative Review38
Effects of Very Low- and High-Frequency Subthalamic Stimulation on Motor Cortical Oscillations During Rhythmic Lower-Limb Movements in Parkinson’s Disease Patients37
Post-Traumatic Stress Disorder and Risk of Parkinson’s Disease in a Veteran Cohort37
Reply to the Letter to the Editor: Stefani A, “Is it too early to Underrate Genetic onto PD Pathogenesis? Reflections on History”37
Evading the Immune System: Immune Modulation and Immune Matching in Cell Replacement Therapies for Parkinson’s Disease36
Atrophy-related corticospinal changes in advanced Parkinson's disease are associated with the genetic etiology of the disease36
Real-World Evaluation of the Feasibility, Acceptability and Safety of a Remote, Self-Management Parkinson’s Disease Care Pathway: A Healthcare Improvement Initiative35
Rapid Voluntary Blinking as a Clinical Marker of Parkinson’s Disease35
The Role of Microelectrode Recording and Stereotactic Computed Tomography in Verifying Lead Placement During Awake MRI-Guided Subthalamic Nucleus Deep Brain Stimulation for Parkinson’s Disease34
Apathy Reflects Extra-Striatal Dopaminergic Degeneration in de novo Parkinson’s Disease34
No Higher Risk-Seeking Tendencies or Altered Self-Estimation in a Social Decision-Making Task in Patients with Parkinson’s Disease34
Are Preformed Fibrils a Model of Parkinson’s Disease?34
Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson’s Disease33
Current Update on Clinically Relevant Sleep Issues in Parkinson’s Disease: A Narrative Review33
A Coalition to Advance Treatments for Parkinson’s Disease, Dementia with Lewy Bodies, and Related Disorders33
0.034883975982666